Wipfli Financial Advisors LLC Buys New Stake in Masimo Co. (NASDAQ:MASI)

Wipfli Financial Advisors LLC bought a new stake in Masimo Co. (NASDAQ:MASIGet Rating) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 839 shares of the medical equipment provider’s stock, valued at approximately $118,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of MASI. Meeder Asset Management Inc. boosted its stake in Masimo by 61.3% during the second quarter. Meeder Asset Management Inc. now owns 221 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 84 shares during the period. Parallel Advisors LLC boosted its stake in Masimo by 38.8% during the second quarter. Parallel Advisors LLC now owns 365 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 102 shares during the period. Archer Investment Corp boosted its stake in Masimo by 62.2% during the second quarter. Archer Investment Corp now owns 391 shares of the medical equipment provider’s stock worth $51,000 after buying an additional 150 shares during the period. EverSource Wealth Advisors LLC purchased a new position in Masimo during the second quarter worth $61,000. Finally, Lazard Asset Management LLC boosted its stake in Masimo by 20.0% during the first quarter. Lazard Asset Management LLC now owns 485 shares of the medical equipment provider’s stock worth $70,000 after buying an additional 81 shares during the period. 87.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Joe E. Kiani bought 31,994 shares of Masimo stock in a transaction on Monday, November 14th. The stock was acquired at an average cost of $123.99 per share, for a total transaction of $3,966,936.06. Following the completion of the acquisition, the chief executive officer now owns 39,778 shares of the company’s stock, valued at approximately $4,932,074.22. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Joe E. Kiani bought 31,994 shares of Masimo stock in a transaction on Monday, November 14th. The stock was acquired at an average cost of $123.99 per share, for a total transaction of $3,966,936.06. Following the completion of the acquisition, the chief executive officer now owns 39,778 shares of the company’s stock, valued at approximately $4,932,074.22. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Joe E. Kiani bought 7,040 shares of Masimo stock in a transaction on Thursday, December 15th. The stock was purchased at an average price of $144.79 per share, with a total value of $1,019,321.60. Following the completion of the acquisition, the chief executive officer now directly owns 46,818 shares of the company’s stock, valued at approximately $6,778,778.22. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 46,818 shares of company stock worth $5,992,495. 9.70% of the stock is owned by corporate insiders.

Masimo Stock Performance

MASI stock opened at $153.45 on Wednesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.12 and a quick ratio of 1.28. The business has a 50-day moving average price of $140.49 and a 200 day moving average price of $142.20. The company has a market capitalization of $8.07 billion, a P/E ratio of 50.81 and a beta of 0.86. Masimo Co. has a 1-year low of $108.89 and a 1-year high of $262.28.

Masimo (NASDAQ:MASIGet Rating) last released its quarterly earnings data on Tuesday, November 8th. The medical equipment provider reported $1.00 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.08. The firm had revenue of $549.30 million during the quarter, compared to the consensus estimate of $533.96 million. Masimo had a return on equity of 18.04% and a net margin of 9.78%. As a group, equities research analysts forecast that Masimo Co. will post 4.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on MASI shares. Needham & Company LLC lifted their price objective on shares of Masimo from $149.00 to $173.00 and gave the stock a “buy” rating in a research note on Monday, December 5th. Jefferies Financial Group began coverage on shares of Masimo in a research note on Wednesday, October 12th. They set a “buy” rating and a $180.00 target price for the company. Piper Sandler lowered their target price on shares of Masimo from $150.00 to $135.00 and set a “neutral” rating for the company in a research note on Wednesday, November 9th. Loop Capital began coverage on shares of Masimo in a research note on Tuesday, September 13th. They set a “buy” rating and a $206.00 target price for the company. Finally, Wolfe Research raised shares of Masimo from a “peer perform” rating to an “outperform” rating and set a $165.00 target price for the company in a research note on Thursday, September 15th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $188.25.

Masimo Profile

(Get Rating)

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Articles

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASIGet Rating).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.